Pterostilbene Composition Augments Oncology Immunotherapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges such as toxicity, side effects, and the development of multi-drug resistance in cancer cells, limiting the effectiveness of conventional therapies and the need for improved strategies to enhance anti-tumor immune responses.
Innovation Solution
A composition containing pterostilbene, administered in combination with anti-cancer antibodies like trastuzumab, to enhance antibody-dependent cellular toxicity and augment antigen-specific immunotherapies, modulating immune activity to increase anti-tumor responses without directly killing cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (chemotherapy, radiation therapy) are used to treat cancer, then cancer cells are targeted and killed, but toxicity and side effects increase and limit the ability of patients to continue treatment
Solution Approach 1:
Pterostilbene acts as an intermediary substance that modulates the immune system to indirectly combat cancer cells. Instead of directly killing cancer cells like conventional therapies, pterostilbene enhances the body's natural immune responses (macrophages, dendritic cells, T cells, NK cells) to recognize and eliminate tumor cells, thereby reducing direct toxicity to healthy tissues while maintaining anti-cancer effectiveness
Solution Approach 2:
The invention leverages the body's own immune system to fight cancer. Pterostilbene stimulates and enhances the natural anti-tumor immune responses already present in the patient's body, including macrophage activation, dendritic cell maturation, T cell proliferation, and NK cell cytotoxicity. This self-service approach allows the patient's immune system to perform the therapeutic function with minimal external intervention and reduced side effects
2Reliability
If multi-drug regimens are used to treat cancer to overcome tumor resistance, then treatment effectiveness is improved, but drug interactions and side effects increase exponentially
Solution Approach 1:
The invention extracts and activates the body's natural immune defense mechanisms as a separate, independent therapeutic pathway. By focusing on immune modulation through pterostilbene rather than combining multiple direct anti-cancer drugs, the treatment simplifies the therapeutic approach while maintaining effectiveness. This extraction of the immune system's anti-tumor potential creates a standalone treatment option that avoids the complexity of multi-drug interactions
3Object-affected harmful factors
If immunotherapy is used to harness anti-tumor immune responses, then direct toxicity to healthy tissues is reduced, but the ability to overcome tumor immune evasion mechanisms is limited
Solution Approach 1:
The invention merges multiple immune activation mechanisms into a single pterostilbene treatment. It simultaneously enhances macrophage phagocytosis, dendritic cell antigen presentation, T cell response, and NK cell cytotoxicity. This multi-target immune modulation approach overcomes tumor immune evasion by attacking through multiple immune pathways concurrently, thereby improving reliability against diverse cancer types without increasing toxicity to healthy tissues
Data Source
AI summary
Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.